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1063-4584/© 2014 Osteoarthritis Research Society InIn this issue of Osteoarthritis and Cartilage, Gaufﬁn and col-
leagues report the ﬁndings of a randomized controlled trial of
arthroscopic partial meniscectomy (APM) vs a physical therapy
regimen in subjects with degenerativemeniscal tears. This carefully
executed study is an important addition to an evolving body of
research on the role of APM and other arthroscopic procedures in
patients with osteoarthritis. Each of the prior trials failed to show
that surgical therapy led to greater pain relief or functional
improvement than the comparators (physical therapy regimens
or sham surgery). Thus, the trial of Gaufﬁn et al. is especially notable
because it documents clinically and statistically signiﬁcantly
greater improvement in pain severity 12 months after enrollment
in the surgically treated subjects than in those receiving an exercise
program. We review these trials of arthroscopic surgery in patients
with OA and meniscal tear in order to place this trial in context and
offer suggestions for clinicians and their patients with this
condition.
The menisci are cartilaginous, semi-lunar shaped knee struc-
tures that confer important load-bearing and stabilizing functions.
Like other cartilaginous intraarticular structures such as the labra of
the shoulder and hip, the menisci are vulnerable to degenerative
tears. The introduction of magnetic resonance imaging in the latter
decades of the 20th century facilitated non-invasive recognition of
meniscal tear, revealing that over one-third of individuals greater
than 50 years old and over three-quarters of persons with knee
osteoarthritis have degenerative meniscal tears1,2. The introduction
of arthroscopic surgical techniques in the same era provided a
minimally invasive means of performing surgery to resect meniscal
tears. Indeed, by the turn of the century, APM for degenerative
meniscal tear had become among the most commonly performed
orthopedic procedures, with over 400,000 performed in the US
alone in 20063.
Over the last 12 years several observations have questioned the
effectiveness of arthroscopic treatment for patients with osteoar-
thritis. First, a randomized controlled trial of arthroscopic lavage
and debridement for osteoarthritis showed considerable beneﬁt
in both arms with no additional beneﬁt in surgically treated pa-
tients compared to those receiving sham surgery4. Similarly, a ran-
domized trial showed that patients with osteoarthritis randomizedternational. Published by Elsevier Lto arthroscopy and those randomized to a physical therapy regimen
both showed substantial improvement with no difference between
the two treatment arms5. On the basis of these trials most treat-
ment guidelines including those of the American Academy of Or-
thopedic Surgeons suggest that arthroscopic lavage and
debridement is not indicated for knee OA .
Most arthroscopies in patients with knee OA are performed to
address symptoms clinicians attribute to meniscal tear, rather
than osteoarthritis per se. Several epidemiologic studies reported
in the last decade have further complicated clinical decision-
making for patients with meniscal tear by showing that these tears
are often asymptomatic. For example, adults in a large community
based sample found to have meniscal tear on MRI were no more
likely to have knee pain than subjects without meniscal tear1. Simi-
larly, subjects withmeniscal tear and osteoarthritis had nomore se-
vere pain than subjects with OA and no tear2. These observations
have challenged the clinical rationale for APM and set the stage
for more rigorous evaluation of APM.
Herrlin and colleagues published the ﬁrst trial to evaluate the ef-
ﬁcacy of APM in patients with degenerative meniscal tear in
20076,7. These investigators enrolled 97 subjects and randomized
half to a rigorous exercise program that emphasized lower extrem-
ity strengthening as well as stretching, conditioning and balance.
The other half received the same exercise program as well as
APM. 28% of subjects randomized to the exercise arm crossed
over to the surgical arm in the ﬁrst 14 months, generally because
of persistent symptoms. In intention to treat analyses (in which pa-
tients are analyzed in the groups they were randomized to, irre-
spective of the treatment they received), the APM group had, on
average, a nine point greater change in KOOS Pain score over
6 months than the exercise-alone group. This difference was not
statistically signiﬁcant, though nine points on the KOOS Pain Scale
is generally considered clinically meaningful8.
In the MeTeOR Trial (Meniscal Tear in Osteoarthritis Research)9,
351 subjects from seven US referral centers were randomized to
APM with an exercise regimen or to the exercise regimen alone.
The exercise regimen was similar to that used by Herrlin et al. By
6 months, 30% of subjects randomized to the PT arm had crossed
over to receive APM. On average, subjects in both arms improvedtd. All rights reserved.
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showed that the group randomized to APM improved 2.7 points
more on the 100-point WOMAC Function Scale than the group ran-
domized to PT. This difference was neither clinically meaningfully
nor statistically signiﬁcant. Yim and colleagues published a similar
trial to the MeTeOR and the Herrlin trials in 201310. This South
Korean study also documentedmarked improvement from baseline
to 1 year in both groupswith no clinicallymeaningful or statistically
signiﬁcant differences between arms in Pain Visual Analog Scale and
Lysholm Scale. In contrast to the Herrlin and MeTeOR trials, there
were also no crossovers in the study of Yim and colleagues.
Sihvonen and colleagues published a sham-controlled trial of
APM in 201311. They included patients withmedial meniscal degen-
erative tear and no radiographic evidence of OA. The sham group
received arthroscopic lavage but no partial meniscal resection.
The investigators documented marked improvements in both
groups in pain and function scores, and greater than 80% satisfac-
tion in both groups with the results of surgery. There were no clin-
ically important or statistically signiﬁcant differences between the
meniscal resection and sham treatment arms in improvement from
baseline in pain or function.
Against this backdrop of high quality trials that failed to demon-
strate superiority of APM over either a PT regimen or sham surgery,
Gaufﬁn and colleagues present in this issue of Osteoarthritis and
Cartilage a randomized controlled trial of APM vs a standardized
PT regimen. As occurred in the Herrlin and MeTeOR trials, a sub-
stantial fraction of subjects crossed over from the PT arm and un-
derwent APM (21% by 12 months). As in each of the studies
reviewed above, both arms improved markedly from baseline to
follow up. However in the intention to treat analysis, the group ran-
domized to APM improved by 10.6 more points on the KOOS Pain
score than the group randomized to PT. This difference was statis-
tically signiﬁcant and clinically meaningful.
Clinicians, investigators, policy makers and payers are chal-
lenged to interpret these ﬁve randomized controlled trials of the ef-
ﬁcacy of APM, four of which did not ﬁnd APM to be statistically
signiﬁcantly superior to the comparator and one which did ﬁnd
APM to be associated with a statistically signiﬁcant, clinically
important advantage. Why the discrepant ﬁndings? One possibility
is that the prior trials missed an important effect because theywere
too small. Indeed, the Herrlin trial demonstrated a 9.6 point differ-
ence between APM and PT groups in improvement in KOOS Pain
but the difference was not statistically signiﬁcant. However theTable I
Summary of ﬁve randomized controlled trials of APM vs comparator in patients with de
Author, year,
country
Sample age,
tear, OA status
#Randomized/
# eligible
Intervention Comparator Primar
Herrlin, 2007,
Sweden
45e64 yo,
medial MT,
KL0-2
96/180 Exercise þ
APM
Exercise Change
(6 mo)
Katz, 2013, US 45 þ yo. MT, KL
0e3
351/1330 Exercise þ
APM
Exercise Change
Functio
Yim, 2013,
South Korea
43e62 yo,
Horizontal
medial MT,
KL0-1
108/162 APM Strength
exercises
Change
Lysholm
Sihvonen, 2013,
Finland
35e65 yo, MT,
KL0-1
146/205 APM Sham
APM
Change
pain w
Lysholm
Gaufﬁn, 2014,
Sweden
45e64 yo, MT,
KL 0-2 (93%
KL0-1)
150/179 Exercise þ
APM
Exercise Change
(12 mo
MT ¼ meniscal tear; KL ¼ KellgreneLawrence Grade; APM ¼ arthroscopic partial menis
To facilitate comparison, VAS, Lysholm, KOOS scores have been transformed in this Tablother trials did not demonstrate clinically important differences be-
tween study arms (Table I).
Another possibility is that substantial cross over from nonoper-
ative to surgical therapy makes the intention to treat analyses in
these trials difﬁcult to interpret. Indeed, in the Herrlin, MeTeOR
and Gaufﬁn trials, 20e30% of subjects assigned to the PT arm
crossed over to surgery, potentially obscuring differences in
outcome between PT and surgery in the intention to treat analyses.
In fact the MeTeOR Trial provided a secondary ITT analysis that
deﬁned ‘failure’ as either a crossover or failure to improve by 8
points on the WOMAC Function scale. Surgery had signiﬁcantly
fewer failures, deﬁned in this fashion, than nonoperative therapy
(33% vs 56%, p < 0.001)9. Thus, the similar outcomes of subjects ran-
domized to APM and those randomized to the comparator in these
trials may have arisen in part from crossover from nonoperative
therapy to APM. That explanation does not explain the ﬁndings of
the trial of Yim et al., which had no crossovers.10
Third, as noted in Table I, APM was associated with substantial
improvement in pain and function in each trial, on the order to
20 to 30 points on the 100 point outcome scales (KOOS Pain in three
instances). Thus, the trials should not be interpreted as showing
that surgery was not beneﬁcial, but rather that in general the trials
showed similar, clinically important improvements in both the sur-
gical arms and the comparator arms.
The ﬁndings of the sham-controlled trial of Sihvonen and col-
leagues merit careful consideration11. The trial shows similar
outcome following APM and sham, suggesting that the effect of
APM may be largely attributable to a placebo, or sham effect. The
potency of sham surgery may relate to the substantial investment
patients make into preparing for surgery and recovery, and the
attendant raising of expectations12,13. Does the similar outcome of
APM and sham surgery vitiate the value of APM as a clinical inter-
vention? We think not. Subjects in both the APM and sham arms
improved by a clinically important amount on standardized mea-
sures of pain and function and over 80% of subjects in each arm
were satisﬁed with the outcome of surgery while over 90% in
each arm stated they would choose surgery again if given the op-
portunity11. We are loathe to suggest eliminating an option associ-
ated with such dramatic pain relief. This would be throwing out
the baby with the bath water. Nor do we d argue that clinicians
should prescribe placebo. Rather, we suggest that these data should
spur further research on harnessing beneﬁts of sham and placebo
interventions. We also note while physical therapy was associatedgenerative meniscal tear
y outcome Difference in outcome
between treatment
arms (ITT analysis)
Improvement in
APM arm
Crossover
in KOOS Pain 9 point difference
favoring APM (NS)
33 pts on KOOS
Pain, 23 points on
Lysholm
28% from PT to
APM by 14 mo
in WOMAC
n (6 mo)
2.4 point difference
favoring APM (NS)
20.9 on WOMAC
Fxn, 24.2 on KOOS
Pain
30% from PT to
APM by 6 mo
in VAS Pain,
Score (24 mo)
2.0 difference in VAS
and 0.1 in Lysholm,
favoring APM (NS)
34 on 100 mm VAS
Pain, 19.2 pts on
Lysholm
None
in pain VAS
exercise,
(12 mo)
1.0 pts on VAS, 1.6 on
Lysholm, favoring APM
(NS)
21.7 pts on
Lysholm, 31 on
100 mm VAS pain
None
in KOOS Pain
)
10.6 points favoring
APM (p < 0.01)
29 pts on KOOS
Pain
21% from PT to
APM by 12 mo
cectomy; ITT ¼ intention to treat.
e to 0e100, 100 ¼ best.
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neither physical therapy nor sham, raising the possibility that the
substantial beneﬁts associated with PT regimens in these trials
may also be due to placebo effect. This too requires further research.
An economic analysis of treatment options for meniscal tear and OA
would be most welcome as well, to guide policy in this clinical area.
Ultimately, patients and their physicians must make integrate
the ﬁndings of these trials and proceed with sensible clinical deci-
sions. For the middle age patient with knee pain and degenerative
meniscal tear, the preponderance of evidence today suggests that
an initial regimen of strengthening-based physical therapy is a
reasonable initial step. Patients who fail to improve following
nonoperative therapy can be referred for APM. We do not know
whether the beneﬁts of surgery (or PT for that matter) are primarily
physiologic or due to placebo effects. This question is ripe for
further research. But we must work with the evidence gathered
from ﬁve rigorous RCTs and summarized in Table I, suggesting
that APM is associated with important gains in pain and functional
status and has a role in the management of this prevalent, disabling
condition.
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